Share Name Share Symbol Market Type Share ISIN Share Description
Huveaux Plc LSE:HVX London Ordinary Share GB0031129579 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 10.50p 0.00p 0.00p - - - 0 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 17.3 0.0 -5.1 - 15.96

Huveaux (HVX) Latest News

Huveaux News

Date Time Source Headline
27/10/201510:13UKREGDods (Group) PLC Half Yearly Report
30/9/201512:22UKREGDods (Group) PLC Director/PDMR Shareholding
More Huveaux News
Huveaux Takeover Rumours

Huveaux (HVX) Share Charts

1 Year Huveaux Chart

1 Year Huveaux Chart

1 Month Huveaux Chart

1 Month Huveaux Chart

Intraday Huveaux Chart

Intraday Huveaux Chart

Huveaux (HVX) Discussions and Chat

Huveaux Forums and Chat

Date Time Title Posts
05/7/201008:48Huveaux - Future FTSE 100 Company600
09/1/200810:56HUVEAUS - WHERES THE ORGANIC GROWTH?258
16/5/200612:34HUVEUX ...publishers looking good2
10/5/200618:59HUVEUX ...publishers looking good1
06/5/200407:42Fall overdone?22

Add a New Thread

Huveaux (HVX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Huveaux trades in real-time

Huveaux (HVX) Top Chat Posts

DateSubject
25/9/2016
09:20
Huveaux Daily Update: Huveaux Plc is listed in the Media sector of the London Stock Exchange with ticker HVX. The last closing price for Huveaux was 10.50p.
Huveaux Plc has a 4 week average price of - and a 12 week average price of -.
The 1 year high share price is - while the 1 year low share price is currently -.
There are currently 151,998,573 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Huveaux Plc is £15,959,850.17.
24/9/2008
23:07
cerrito: and now 22.05% No idea filipe google reveals nothing and HVX seems to be the only company where they have a notifiable interest will try to phone the company to find out This should be a plus for the share price but apart from a possibility of a corporate action there is nothing to make this move up ie we are not expecting any results or indeed a trading statement in the near future nor is there any major business development expected.
11/7/2008
16:54
psolomons: This seems oversold to me. The company issued a very upbeat trading statement recently after all the trauma earlier in the year and yet the share price is resting at near record lows. Unless HVX have been misleading the city there should be some re-rating on the way.
17/2/2008
12:01
haroldthegreat: have noticed that a small amount of purchases move the share price by quite a large amount. is this normal?
13/11/2007
11:43
cerrito: Ran through the profit forecast figures, something I did not get round to doing when they came out the first time. They are talking about H2 EBITDA being £5/6m similar to H2 06 of £5.4. That of course does not recognize that in H207 they will get full benefit of Letts and Leckie and Leckie acquisitions whereas in H206 they only got partial benefit. Furthermore in H2 interest costs will be higher than the £674k of H2 06 and more like the £752k of H1 07. To have a stab at post tax profit for the full year, if you say ebitda is £6m , you double the first half interest figure to give £1.5m, and then double the first half depreciation and amortization to give you £3.7m and say tax is £0.8m you have a breakeven figure. All pretty back of the envelope but does explain the current share price. I am neither selling or buying.
26/7/2007
22:03
cerrito: Good to see healthy director buying today. I guess that has given me more confidence than the figures have. For all the song and dance of the problems of healthcare in France the decline in learning's ebitda from £926K in the same semester last year to £ 209K was more important in the fall of overall corporate EBITDA from £1780K to £963k. Also note that Political EBITDA was £195k compared to £603k in the first half of 2005. I am comfortable with the top ups I have made in the thirties in the last couple of weeks. That having been said share price progress will be slow. There presumably will be no major acquisitions this year given their share price although they do have a modest borrowing capacity. For them to reach the consensus forecast of £4.22m they will need to make £5.3m in the second half which will be quite a stretch, especially as there are no signals given of an imminent turn around in healthcare's fortunes. If the Tories' woes continue that will be a downer for Politics especially for the party conference publications but I am hopeful that they will be able to beat the £2m EBITDA of the second half of last year. Education will be key.
05/7/2007
13:09
broomsticks: I hate to admit this but whilst Huveaux claims in its Trading Update of 26 June 2007, RNS Number:04212 that its present problem is "Our Healthcare Division in France has seen a significant drop in sales revenue as compared to the first half of 2006." that is not the reason for my decision to sell some of my shares. I disposed of them when there was a lack of feedback from the MediaFinance 2007 conference. That omission added to what was and still is my unease about the axing of BBC Jam. Not the axing per se because nobody can be pleased that 200 people lost their jobs, it just struck me as odd that the commercial sector had complained about the impact BBC Jam had on their business when the website was perceived by professionals as having basic design errors both technical and educational, as a consequence of which its traffic was minimal. This £150m website was in fact struggling to meet the licence conditions set by the BBC Trust. Further to that it had been criticised by the Content Advisory Board as not complying with its remit. It was from this setup that Andy Ware joined Huveaux. Another worrying point is that Fenman twice extended its sale. Letts partnership with TutorVista should prove to be a positive move by Huveaux but I am mindful of the fact that TutorVista is a young company backed by a venture capitalist awash with funds. Having said all that I intend to hold on to my remaining shares. The present share price makes it tempting to buy back some shares, but..................hmmmm aimo,dyor
04/4/2007
12:54
jlabrey: It is clear that Epic is driving value across the Group. I was very interested to see the appointment of Andy Ware as the Director of the new Education Division (there are now four business divisions). He is a former director of learning at the BBC. It seems Huveaux wants to be a consolidator in the education publishing sector, with many companies exiting this space at the moment because they don't want to invest in digitalisation. The revision guides businesses will then become the nucleus of a much bigger division. The question (and risk) is how any acquistion(s) will be funded going forward. Borrowing is modest but there is probably only another £18m available from this route to maintain prudence. Then it's cash and shares. I would like to see the Group potentially exploring the joint venture model to limit earnings dilution, which could give us a slice of a much more significant market. On a separate note, I saw that Jane's Information Group was put up for sale last week by their Canadian owners with an expected price tag of £50 million. On HVX's share price performance, it is disappointing that the market has not spotted the value here but it gives opportunities to add and, hopefully, make bigger gains in the long term... The management seem to be doing all the right things to secure growth.
15/2/2007
19:17
broomsticks: jlabrey, Thanks for that I noticed earlier that Reed Elsevier has put its education division up for sale. I haven't looked at the whole sector but see that Huveaux's share price appears to have suffered as a result. It is probably to Reed Elsevier's advantage to sell off its education division, it will certainly have a leaner image after the disposal. It gives a bad impression of the whole educational sector when companies appear unable to successfully incorporate an educational division within their boundaries of expertise. For me that is where Huveaux differs in that it is able to fully utilise its education division through the astute use of Epic's expertise and flexibility within the fields of blended and e-learning. If anyone is interested and has some time to listen to Donald Clark the former CEO of Epic Group Plc I have placed some links below. For information Donald Clark has been associated with e-learning for more than 20 years. The following podcasts are interviews of him by Steven Walsh of Kineo. They give some clues to the legacy that Donald Clark has given to Epic and consequently the ethos in which Huveaux operates. http://www. http://www.kineo.co.uk/audio/dc_clip1.mp3 http://www.kineo.co.uk/audio/dc_clip3.mp3 http://www.kineo.co.uk/audio/dc_clip4.mp3 Donald Clark gives his views on the educational value of blogging and why he personally blogs as a means of communication. http://www.kineo.co.uk/audio/dc_clip2.mp3 aimo,dyor
05/2/2007
17:55
barbra2: could the 300,000 'T' transactions be sales instead of buys? I think they are - that's why the share price has not moved up despite the large number of buys during the day. Buyers today have inadvertantly help someone to offload their holding (possibly) Sorry for stating the obvious! Hope I will be proved wrong as I have also bought today.
15/8/2005
19:23
psolomons: Trouble is if HVX have to pay more for epic because of the interest from futuremedia it will be reflected in a downward move of the HVX share price. Deal needs to be sorted before any major share price moves. imho.
Huveaux share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20160925 20:52:04